The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A Pharmacogenomic Landscape in Human Liver Cancers
Open accessAbstract
SUMMARY Liver cancers are highly heterogeneous with poor prognosis and drug response. A better understanding between genetic alterations and drug responses would facilitate precision treatment for liver cancers. To characterize the landscape of pharmacogenomic interactions in liver cancers, we developed a protocol to establish human liver cancer cell models at a success rate around 50% and generated Liver Cancer Model Repository (LIMORE) with 81 cell models. LIMORE represented genomic and transcriptomic heterogeneity of primary cancers. Interrogation of the pharmacogenomic landscape of LIMORE discovered unexplored gene-drug associations, including synthetic lethalities to prevalent alterations in liver cancers. Moreover, predictive biomarker candidates were suggested for the selection of sorafenib-responding patients. LIMORE provides a rich resource facilitating drug discovery in liver cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556 · cited 1×
“Cufflinks algorithm (Trapnell et al., 2010) was used to calculate gene expression levels.”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 3×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript REAGENT or RESOURCE SOURCE IDENTIFIER Primer: MYC Reverse: ttgaggggcatcgtcgcgggaggctg This paper N/A Primer: β-catenin Forward: cttccatcccttcctgctta This paper N/A Primer: β-catenin Reverse: aggtgctgtctgtctgctcta This paper N/A Primer: GSD…”
MethodThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“of predictive biomarkers has been proposed to select responsive patients (Holohan et al., 2013), which apparently requires systematic knowledge of pharmacogenomic landscape in liver cancers.”
BackgroundChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199
Self-citationComprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citation
Cited by
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Self-citationThe Curious Case of the HepG2 Cell Line: 40 Years of Expertise
Arzumanian, V. A., Kiseleva, O. I., & Poverennaya, E. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313135 · Cited by 387
A targetable LIFR−NF-κB−LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis
Yao, F., Deng, Y., Zhao, Y., Mei, Y., Zhang, Y., Liu, X., Martinez, C., Su, X., Rosato, R. R., Teng, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27452-9 · Cited by 322
Self-citationDisease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients
(DeCOI), G. C.-1. O. I., Aschenbrenner, A. C., Mouktaroudi, M., Krämer, B., Oestreich, M., Antonakos, N., Nuesch-Germano, M., Gkizeli, K., Bonaguro, L., Reusch, N., et al. (2021) · Genome Medicine · doi:10.1186/s13073-020-00823-5 · Cited by 255
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154
Self-citationMolina-Sánchez, P., Ruiz de Galarreta, M., Yao, M. A., Lindblad, K. E., Bresnahan, E., Bitterman, E., Martin, T. C., Rubenstein, T., Nie, K., Golas, J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.08.015 · Cited by 117
Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80
Self-citationLiver organoids: established tools for disease modeling and drug development
Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000105 · Cited by 37
Developing Liver Microphysiological Systems for Biomedical Applications
Wang, J., Wu, X., Zhao, J., Ren, H., & Zhao, Y. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302217 · Cited by 27
Lai, X., Zhang, Y., Li, M., Yu, S., Wang, S., Zhang, S., Niu, H., Chen, L., Lan, X., Zhang, J., et al. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23878 · Cited by 11
Wang, M., Yan, X., Dong, Y., Li, X., & Gao, B. (2024) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1012113 · Cited by 9
“Finally, to investigate the differences in drug sensitivity across subtypes, we applied the SVM_10 model to the LIMORE dataset, containing the mutation, RNA, and drug response data for 81 HCC cell lines [52].”
Method
Metadata
- Authors
- Qiu, Z., Li, H., Zhang, Z., Zhu, Z., He, S., Wang, X., Wang, P., Qin, J., Zhuang, L., Wang, W., Xie, F., Gu, Y., Zou, K., Li, C., Li, C., Wang, C., Cen, J., Chen, X., Shu, Y., Zhang, Z., Sun, L., Min, L., Fu, Y., Huang, X., Lv, H., Zhou, H., Ji, Y., Zhang, Z., Meng, Z., Shi, X., Zhang, H., Li, Y., & Hui, L.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 36
- Issue
- 2
- Pages
- 179-193.e11
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2996358113
- Cited by
- 203
- References
- 35
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.